In this work the thermal signature of melanoma and non-melanoma skin cancers is investigated in order to be used as a non-invasive aid in the diagnosis and the vascular assessment of these types of skin cancers. Thirty patients with melanoma and non-melanoma skin cancers were examined in order to obtain their temperature profile. The results show that there is a characteristic thermal signature for different types of skin neoplasms which not necessarily depend exclusively on their vascularity. Basal cell carcinomas and squamous cell carcinomas showed a larger range of vascularity, while the thermal profile remained basically constant for squamous cell carcinomas and varied a lot for basal cell carcinomas. In the case of melanomas they showed a high vascularity and an almost constant thermal signature which indicates that metabolic heat production is more relevant in assesing agressiveness. Basal cell carcinomas showed a big range in temperature profiles and a big range in vascularity, a correlation between vascularity and temperature profile was observed when analyzing each subtype of basal cell carcinoma, which indicates that the thermal behavior of basal cell carcinomas is highly dependent on their subtype. With squamous cell carcinoma a big range in vasculature was measured however the temperature range of their thermal profile did not change significantly which indicates that there might be a metabolic heat production-vasculature parameter that appears to remain constant. These results are a step forward in designing a thermal model for skin neoplasms.

No abstract

No abstract

No abstract

CD25 on CD117+ mast cells, (iv) serum tryptase levels >20 mL plus one or more "C-findings"(cytopenia, malabsorption, osteolysis, liver impairment and ascites). 7 Our patient had the major criteria, two minor criteria and C findings.Aggressive systemic mastocytosis is a difficult to treat condition and treatment options include antihistaminics, H2 antagonists, disodium cromoglygate, corticosteroids, psoralen ultraviolet A, interferon alpha-2b and tyrosine kinase inhibitors. There is limited information in the literature to guide treatment of patients such as ours, with multisystem infiltration of mast cells causing multiple organ failure.Tyrosine kinase inhibitors have been shown to cause mast cell apoptosis, but their use in infants or neonates has been rarely reported. 8 Antibiotics are indicated in cases with features of sepsis. This case highlights the rapidly progressing course of aggressive systemic mastocytosis in a neonate and the need to develop aggressive treatment options to improve prognosis in patients, especially of this age group, which is otherwise very poor. Declaration of patient consentThe authors certify that they have obtained all appropriate patient consent forms. In the form, the legal guardian has given his consent for images and other clinical information to be reported in the journal. The guardian understands that names and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.